Driehaus Capital Management LLC C4 Therapeutics, Inc. Transaction History

Driehaus Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $1.41 Million - $2.67 Million	-260,752 Reduced 42.98%	345,969 $2.04 Million
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $75,056 - $119,361	9,347 Added 1.56%	606,721 $5.32 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $1.23 Million - $6.44 Million	243,462 Added 68.79%	597,374 $4.5 Million
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $135,892 - $225,897	-6,798 Reduced 1.88%	353,912 $8.59 Million
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $8.25 Million - $13.2 Million	-280,689 Reduced 43.76%	360,710 $11.6 Million
Q3 2021 Nov 15, 2021	BUY	$35.91 - $50.5 $15.6 Million - $21.9 Million	433,816 Added 208.98%	641,399 $28.7 Million
Q2 2021 Aug 16, 2021	BUY	$30.39 - $42.18 $6.31 Million - $8.76 Million	207,583 New	207,583 $7.86 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.